At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 178 enrolled
Drug / intervention
Cyclosporine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
In Brief
A Phase 2 clinical trial evaluating Cyclosporine and CP-690,550 for Kidney Transplantation. Completed, enrolled 178 participants across 65 sites in 15 countries.
Detailed Summary
This is a study that will follow transplant patients from Study A3921030 to monitor for long term safety, tolerability and efficacy for 5 additional years, except in Portugal where the study will follow transplant patients through Month 36 posttransplant. Patients will continue their study medications that were previously assigned.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplantation
CountriesAustralia, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Norway, Poland, Portugal, South Korea, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartAug 2008
Primary CompletionMar 2015
Study CompletionJun 2015
TodayJul 2026
First PostedApr 15, 2008
Enrollment StartAug 1, 2008
Primary CompletionMar 1, 2015
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 18.2 years ago
Interventions
Cyclosporinedrug
Standard of care
CP-690,550drug
CP-690,550 tablets dosed BID Months 12-72
CP-690,550drug
CP-690,550 tablets dosed BID Months 12-72